Table 2.
Characteristics of participants who underwent EIB tests
| All tested (n = 98) | Dyspnea (n = 41) | Nondyspnea (n = 57) | p‐value | |
|---|---|---|---|---|
| Age (years), mean (SD) | 15.8 (± 0.1) | 16 (±0.2) | 15.8 (±0.1) (15,17) | >0.99 |
| Females, n (%) | 57 (58.2) | 29 (70.7) | 28 (49.1) | 0.053 |
| Weekly training hours, median | 12.5 | 12.5 | 12.5 | >0.99 |
| BMI, mean (SD) | 22.1 (±6.0) | 21.1 (±6.0) | 22.2 (±6.1) | 0.52 |
| Overweight and obesitya (%) | 18 (19.4) | 7 (18.4) | 11 (20) | 0.85 |
| FEV1 % predictedb, mean (SD) | 95.8 (±9.9) | 97.5 (±10.8) (±10.8) | 94.6 (±9.2) | 0.92 |
| Current asthmac, n (%) | 21 (21.4) | 18 (43.9) | 3 (5.2) | <0.001 |
| Rhinitis, n (%) | 26 (27.6) | 13 (33.3) | 13 (23.6) | 0.30 |
| Wheeze, n (%) | 34 (35.4) | 21 (52.5) | 13 (23.6) | 0.002 |
| Day time Dyspnea, n (%) | 11 (11.2) | 6 (15) | 5 (8.6) | 0.34 |
| Nocturnal Dyspnea, n (%) | 2 (2) | 0 | 2 (3.4) | 0.51 |
| ICSd, n (%) | 13 (13.5) | 9 (23.1) | 4 (7.1) | 0.035 |
| SABAd, n (%) | 28 (29.2) | 18 (46.2) | 10 (17.5) | 0.002 |
| LABAd, n (%) | 4 (4.3) | 2 (5.4) | 2 (3.6) | >0.99 |
| LTRAd, n (%) | 1 (1.1) | 0 (0) | 1 (1.8) | >0.99 |
| Exercise tests, positive/all tested, n (%) | ||||
| EIB test | 24/98 (24.5) | 8/41 (19.5) | 16/57 (28.1) | 0.46 |
| CLE test | 8/75 (10.7) | 5/34 (14.7) | 3/41 (7.3) | 0.46 |
P‐value: Dyspnea versus Nondyspnea. BMI, body mass index (kg/m2); ICS, inhaled corticosteroids; SABA, short‐acting β2‐agonists; LABA, long‐acting β2‐agonists; LTRA, leukotriene receptor antagonist; EIB test, exercise‐induced bronchoconstriction test; CLE test, continuous laryngoscopy exercise test.
Available data: all 98 subjects responded to all the questions in the questionnaire except wheeze, ICS and SABA n = 96, rhinitis n = 94, BMI, overweight and obesity, LABA and LTRA n = 93.
Overweight and obesity defined as BMI ≥ 85th percentile.
Refolded before exercise‐induced bronchoconstriction test.
Self‐reported physician‐diagnosed with symptoms and/or medication excluding SABA only.
Any use in last three months.